FDA OKs Lucentis to treat diabetic retinopathy

 The Food and Drug Administration approved Genentech’s drug Lucentis to treat all forms of diabetic retinopathy — a complication of diabetes that leads to vision loss.

Advertisement
By: Mackenzie Bean

Lucentis represents the first FDA-approved treatment for diabetic retinopathy patients with or without diabetic macular edema.

The FDA previously approved the drug to treat various eye conditions, including wet age-related macular degeneration, diabetic macular edema and myopic choroidal neovascularization.

More articles on supply chain:

Global pharmerging market to reach $1.4B by 2025
FDA OKs Tecentriq for advanced bladder cancer
Bristol-Myers will license drugs to Biogen, Roche for $470M

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

  • Abbott launches residual cancer test

    Abbott has launched an updated version of its Oncodetect blood test, which helps clinicians determine whether cancer remains in patients…

    By: Elizabeth Gregerson

  • Supply chain leaders' $1M wish lists

    Becker’s asked supply chain leaders: If you had an extra $1 million for your supply chain budget, where would it…

    By: Ella Jeffries

  • 10 systems seeking supply chain leaders

    As hospitals redefine the role of supply chain leaders to focus on enterprise strategy, digital transformation and resilience, health systems…

    By: Ella Jeffries
Advertisement

Comments are closed.